Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;24(1):199-214.
doi: 10.1016/j.hoc.2009.11.002.

Hydroxyurea for children with sickle cell disease

Matthew M Heeney  1 , Russell E Ware
Affiliations
Review

Hydroxyurea for children with sickle cell disease

Matthew M Heeney et al. Hematol Oncol Clin North Am. 2010 Feb.

Abstract

Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). Hydroxyurea is a prototypic therapeutic option; it can be administered with minimal side effects, has a relatively wide therapeutic window, and has mechanisms of action that address pathophysiologic pathways of sickling, vaso-occlusion, hemolysis, and organ damage. There are limited data regarding hydroxyurea's ability to prevent or diminish organ dysfunction, and the long-term risks of hydroxyurea therapy remain incompletely defined. Although clinical trials are underway to address long-term issues, hydroxyurea remains an effective but underutilized therapy for SCD.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Guideline for initiating, modifying, and monitoring hydroxyurea therapy (see text for further details). Asterisk indicates prehydroxyurea laboratory studies that are performed to help determine the etiology of potential treatment related laboratory changes or toxicities (eg, transaminitis, macrocytosis, and reticulocytopenia).
Fig. 2
Fig. 2
Changes in complete blood cell count parameters and erythrocyte morphology in association with hydroxyurea therapy, from dose initiation through escalation to MTD. The initial panel shows blood counts and the peripheral blood smear at dose initiation, with hemolytic anemia and leukocytosis evident along with sickled forms. The second panel is after 8 weeks of hydroxyurea therapy (at approximately 20 mg/kg/d) with some macrocytes and anisocytosis present, along with reductions in the ANC and ARC; the dose was escalated (to approximately 25 mg/kg/d). The third panel is after 20 weeks of hydroxyurea therapy, with less anemia and sickling, more macrocytosis, and modest myelosuppression; the dose was escalated (to approximately 30 mg/kg/d). The fourth panel is after 22 months of hydroxyurea therapy (at MTD of 27 mg/kg/d); there is improved Hb with pronounced macrocytosis and no sickled forms, along with modest neutropenia and reticulocytopenia. ARC, absolute reticulocyte count; Hb, hemoglobin; HU, hydroxyurea.
See this image and copyright information in PMC

References

    1. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–16. - PubMed
    1. Steinberg MH, Rosenstock W, Coleman MB, et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood. 1984;63(6):1353–1360. - PubMed
    1. Baum KF, Dunn DT, Maude GH, et al. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med. 1987;147(7):1231–1234. - PubMed
    1. Phillips G, Jr, Coffey B, Tran-Son-Tay R, et al. Relationship of clinical severity to packed cell rheology in sickle cell anemia. Blood. 1991;78(10):2735–2739. - PubMed
    1. Powars DR. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol. 1991;28(3):202–208. - PubMed

Publication types